BMS-777607

For research use only. Not for use in humans.

目录号:S1561 别名: BMS 817378

BMS-777607 Chemical Structure

CAS No. 1025720-94-8

BMS-777607 (BMS 817378)是一种Met相关的抑制剂,作用于c-MetAxlRonTyro3,在无细胞试验中IC50分别为3.9 nM,1.1 nM,1.8 nM和4.3 nM,作用于Met相关靶点比作用于Lck, VEGFR-2,和TrkA/B选择性高40倍,比作用于其他受体和非受体激酶选择性高500多倍。Phase 1/2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2041.38 现货
RMB 976.53 现货
RMB 1706.13 现货
RMB 5498.71 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的BMS-777607发表文献43篇:

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 BMS-777607 (BMS 817378)是一种Met相关的抑制剂,作用于c-MetAxlRonTyro3,在无细胞试验中IC50分别为3.9 nM,1.1 nM,1.8 nM和4.3 nM,作用于Met相关靶点比作用于Lck, VEGFR-2,和TrkA/B选择性高40倍,比作用于其他受体和非受体激酶选择性高500多倍。Phase 1/2。
特性 BMS 777607是有效的Met家族成员抑制剂,比作用于Lck, VEGFR-2,和TrkA/B的选择性高40多倍,比作用同样其他受体和非受体激酶选择性高500多倍。
靶点
Axl [1]
(Cell-free assay)
RON [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
Tyro3 [1]
(Cell-free assay)
Mer [1]
(Cell-free assay)
1.1 nM 1.8 nM 3.9 nM 4.3 nM 14 nM
体外研究

BMS-777607是ATP竞争性Met激酶选择性抑制剂,有效抑制c-Met自磷酸化,作用于GTL-16细胞裂解物, IC50为20 nM,且选择性抑制Met驱动的肿瘤细胞系如GTL-16细胞系, H1993和 U87增殖。[1] BMS-777607 作用于DU145前列腺癌细胞,抑制肝细胞生长因子 (HGF)引起的c-Met自磷酸化, IC50<1 nM 。BMS 777607对肿瘤细胞生长作用效果不大,但是作用于PC-3 和DU145 细胞,抑制HGF诱导的细胞分散。BMS 777607作用于这两种细胞,也抑制刺激的细胞迁移和入侵,IC50<0.1 μM,这种作用存在剂量依赖性。[2] BMS 777607(~10 μM)作用于高度转移性鼠科KHT细胞2小时,有效清除自磷酸化的c-Met水平,IC50为10 nM,不影响全部 c-Met,导致下游信号分子包括 ERK, Akt, p70S6K 和 S6受抑制,这种作用存在剂量依赖性。纳摩尔级BMS-777607(~1 μM)处理24小时,有效抑制KHT细胞分散,活动,和入侵,这与MET基因抑制相关,适当影响细胞增殖和集落形成。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC-3 MYfGeY5kfGmxbjDhd5NigQ>? MofuNE4yKM7:TR?= Ml\QSG1UVw>? NH;PeW9mgGirYnn0d{BqdmirYnn0c5J6KGWoZnXjeEBwdiCKR1[tbY5lfWOnZDDj[YxtKHOlYYT0[ZJqdmd? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0N{c,OjB3MUW5OFM9N2F-
DU145 NVLTXVczTnWwY4Tpc44h[XO|YYm= Mn;NNE4yKM7:TR?= M3fOXmROW09? M3fXdIV5cGmkaYTzJIlvcGmkaYTvdpkh\W[oZXP0JI9vKEiJRj3pcoR2[2WmIHPlcIwhe2OjdITldolv\w>? M3;hcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQ{Lz5{MEWxOVk1OzxxYU6=
PC-3 NHLT[IpHfW6ldHnvckBie3OjeR?= MmX5NE4xOSEQvF2= NGTXVY9FVVOR MUDzeZBxemW|c3XzJGhITi2rbnT1Z4VlKGOnbHygcYloemG2aX;u MomzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFMoRjJyNUG1PVQ{RC:jPh?=
DU145 MUXGeY5kfGmxbjDhd5NigQ>? Mm\XNE4xOSEQvF2= NFryeY1FVVOR MYDzeZBxemW|c3XzJGhITi2rbnT1Z4VlKGOnbHygcYloemG2aX;u MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0N{c,OjB3MUW5OFM9N2F-
PC-3 NYT2fo42TnWwY4Tpc44h[XO|YYm= M1;RflAvOSEQvF2= NWTsfWltTE2VTx?= NV;Z[3U{cW2yYXnyd{BJT0ZvbXXkbYF1\WRiY3XscEBqdn[jc3nvci=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0N{c,OjB3MUW5OFM9N2F-
DU145 NXKw[5plTnWwY4Tpc44h[XO|YYm= MonoNE4yKM7:TR?= M{Tq[WROW09? Ml7EbY1x[Wm{czDIS2YudWWmaXH0[YQh[2WubDDpcpZie2mxbh?= NGX4RpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1Oyd-MkC1NVU6PDN:L3G+
PC-3 M2HoW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUP6ZlI5hjFyIN88US=> MluwSG1UVw>? NWTUVIxTemWmdXPld{Bk\WyuIIDyc4xq\mW{YYTpc44> M{nMdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQ{Lz5{MEWxOVk1OzxxYU6=
KHT NUnkW2hMU2mwYYPlJIF{e2G7 MlHaSG1UVw>? NF64WXBjdG:la4OgeIhmKGNvTXX0JJNq\26jbHnu[{Bx[XSqd3H5JJdqfGhiSVO1NEBw\iBzMDDuUS=> MoC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OE[1NlMoRjJ{Mki2OVI{RC:jPh?=
KHT MUDGeY5kfGmxbjDhd5NigQ>? NFLa[5h,OSEQvF2= M1;zTmROW09? NYnwdoVneHKndnXueJMhe3CxboThcoVwfXNiS1jUJINmdGxic3PheJRmemmwZzD3bZRpKEmFNUCgc4YhOC5zLUCuOUDPxE1? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6NkWyN{c,OjJ{OE[1NlM9N2F-
KHT NFfOeplHfW6ldHnvckBie3OjeR?= NVfSd4oxhjBwNTFOwG0> MWjEUXNQ M1[wWIlvcGmkaYTzJINmdGxibXnndoF1cW:w M3XJR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mki2OVI{Lz5{MkK4OlUzOzxxYU6=
KHT MWHGeY5kfGmxbjDhd5NigQ>? NEnXWXl,OC53IN88US=> NHjLT4JFVVOR MkLCbY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? M{HBelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mki2OVI{Lz5{MkK4OlUzOzxxYU6=
KHT MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NH;afZV,OTBizszN M2\lUmROW09? MX\pcohq[mm2czDLTHQh[2WubDDwdo9tcW[ncnH0bY9v NIDvSVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4OlUzOyd-MkKyPFY2OjN:L3G+
T-47D M4e4Umdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmTlglUh|ryP MmXySG1UVw>? MlfNbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M37LNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NE[4OVI6Lz5{M{S2PFUzQTxxYU6=
ZR-75-1 MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYD+OUDPxE1? MkH1SG1UVw>? NWm4OY1rcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR4OEWyPUc,OjN2Nki1Nlk9N2F-
T-47D M2e5N2Z2dmO2aX;uJIF{e2G7 MV6xNEDPxE1? MXPEUXNQ NX7DdW44UW6mdXPld{Bxd2y7cHzvbYR6KGK7IEi2JEU> NETUcY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S2PFUzQSd-MkO0Olg2Ojl:L3G+
ZR-75-1 Mn7CSpVv[3Srb36gZZN{[Xl? Mn7iNVAh|ryP M{PidmROW09? NGroU5FKdmS3Y3XzJJBwdHmybH;p[Jkh[nliOEil M13RNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NE[4OVI6Lz5{M{S2PFUzQTxxYU6=
T-47D Ml\JSpVv[3Srb36gZZN{[Xl? MlGxNVAh|ryP MlKxSG1UVw>? MWfpcohq[mm2czDBWXJMNUJiZoXuZ5Rqd25iYX7kJIlv\HWlZYOgbZR{KHC{b4TlbY4h\GWpcnHkZZRqd25? Mn7nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2Nki1NlkoRjJ|NE[4OVI6RC:jPh?=
CHRF MWHGeY5kfGmxbjDhd5NigQ>? M4\Hd|ExKM7:TR?= MlPXSG1UVw>? NEO3[YhqdmirYnn0d{Bk\WyuIHTpeol{cW:w NXe2dI45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFQ6ODBpPkK1N|A1QTByPD;hQi=>
HPDE NGP4ZllHfW6ldHnvckBie3OjeR?= M2HUUFExKM7:TR?= NUe0dJIyTE2VTx?= M3vNTYJtd2OtczDjc45{fGm2dYTpeoUh[WO2aY\heIlwdiCjbnSg[IVkemWjc3XkJGFMXCC|aXfuZYxqdmd? M3;xb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe3N|E1Lz5{NkS3O|MyPDxxYU6=
U118MG NEW2cGZMcW6jc3WgZZN{[Xl? MlPyglMh|ryP NX2xZ2Y2TE2VTx?= MoX5Zoxw[2u|IFHYUEBxcG:|cHjvdplt[XSrb36= Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6NEi1NlQoRjJ4OES4OVI1RC:jPh?=
SF126 Mmi2T4lv[XOnIHHzd4F6 NV;FVFlphjNizszN MX7EUXNQ Mn;RZoxw[2u|IFHYUEBxcG:|cHjvdplt[XSrb36= NF\jcZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki0PFUzPCd-Mk[4OFg2OjR:L3G+
U118MG M33afWN6fG:6aXPpeJkh[XO|YYm= MnG2NVIvPSEQvF2= M1rEe2ROW09? M1zmR4Rm[3KnYYPld{BodGmxbXGgZ4VtdCC4aXHibYxqfHl? NXjoc5I4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4OFg2OjRpPkK2PFQ5PTJ2PD;hQi=>
SF126 MXLDfZRwgGmlaYT5JIF{e2G7 MWKxNk42KM7:TR?= NXH6U3BjTE2VTx?= MWTk[YNz\WG|ZYOg[4xqd22jIHPlcIwhfmmjYnnsbZR6 MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh2OEWyOEc,OjZ6NEi1NlQ9N2F-
U118MG NF24WnVCeG:ydH;zbZMh[XO|YYm= Mle5NVIvPSEQvF2= NXHudHhQTE2VTx?= MVPpcoR2[2W|IHfsbY9u[SClZXzsJIFxd3C2b4Ppdy=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh2OEWyOEc,OjZ6NEi1NlQ9N2F-
SF126 MUDBdI9xfG:|aYOgZZN{[Xl? NUnyWItpOTJwNTFOwG0> MWTEUXNQ NWj4O4x[cW6mdXPld{BodGmxbXGgZ4VtdCCjcH;weI9{cXN? NYTBZXVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4OFg2OjRpPkK2PFQ5PTJ2PD;hQi=>
U118MG MoOwSpVv[3Srb36gZZN{[Xl? MX6xNk42KM7:TR?= NG\vV|ZFVVOR M4n1eYJtd2OtczDncIlwdWFiY3XscEBucWe{YYTpc44h[W6mIHnueoF{cX[nIHfyc5d1cCCyYYT0[ZJv MknRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6NEi1NlQoRjJ4OES4OVI1RC:jPh?=
SF126 MmDtSpVv[3Srb36gZZN{[Xl? NWqyW445OTJwNTFOwG0> NEXQeWtFVVOR M4TUSIJtd2OtczDncIlwdWFiY3XscEBucWe{YYTpc44h[W6mIHnueoF{cX[nIHfyc5d1cCCyYYT0[ZJv M1;hWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OES4OVI1Lz5{Nki0PFUzPDxxYU6=
GTL16 NIjFZplHfW6ldHnvckBie3OjeR?= M1PvcFMxKG2rboO= NVHBTZFCUW6qaXLpeIlwdiCxZjDN[ZQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGdVVDF4IHPlcIx{KGGodHXyJFMxKG2rboOsJGlEPTBiPTCwMlAzKM7:TT6= MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NkC3NVEoRjF7Mk[wO|EyRC:jPh?=
GTL16 NXz2fIdnSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NF63NJo4OiCqcoO= NUPzUYl7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBO\XRvZHXw[Y5l\W62IHj1cYFvKEeWTEG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkGg{txONg>? M{e4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mk[wO|EyLz5zOUK2NFcyOTxxYU6=
NCI-H1993 M{XCVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MorkO|IhcHK| MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF3leE1l\XCnbnTlcpQhcHWvYX6gUmNKNUhzOUmzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkG1JO69VS5? NH7UOmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK2NFcyOSd-MUmyOlA4OTF:L3G+
U87 NVXWOZY4SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MlTNO|IhcHK| NGnCOIJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JG1mfC2mcnn2[Y4hcHWvYX6gWVg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTBiPTCwMlE3KM7:TT6= M{HpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mk[wO|EyLz5zOUK2NFcyOTxxYU6=
BAF3 NEnIbGxEgXSxdH;4bYNqfHliYYPzZZk> NUTBU3pJPzJiaILz MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXFCULV3leEBie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOsJGlEPTBiPTCwMlE5QDRizszNMi=> MkLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OUK3O|QoRjJ2N{myO|c1RC:jPh?=
DU145 NVrMbXlQSW62aXnueoF{cX[nIHHzd4F6 NVXQW29yOSCqch?= Ml35RY51cWmwdnHzbZZmKGGldHn2bZR6KGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiSFfGMYlv\HWlZXSgZ4VtdCCvb4TpcIl1gSCycnXpcoN2[mG2ZXSg[o9zKDFiaIKgZoVnd3KnIFjHSkB1emWjdH3lcpQhdWWjc4Xy[YQh[W[2ZYKgNlQhcHK|IHL5JINmdGxic3PheJRmemmwZzDhd5NigSxiSVO1NEA:KDBwMjFOwG0v Moq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N|AoRjJ2OUCwPFMxRC:jPh?=
MKN45 NYfk[JU3S3m2b4TvfIlkcXS7IHHzd4F6 NFvGUpE4OiCqcoO= M1H3OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1MVjR3IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvOjh3ODFOwG0v NFznTWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe5Nlc4PCd-MkS3PVI4PzR:L3G+
NCI-H1993 NWqxVpRyS3m2b4TvfIlkcXS7IHHzd4F6 M4jLSVQ5KGi{cx?= NYK5SldwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixPVk{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxMlExQCEQvF2u NVm5eo46RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
GTL16 NVG5fnBuTnWwY4Tpc44h[XO|YYm= MYi2MlI2KG2pL3vn MmWxR41igCCrbjDoeY1idiCJVFyxOkBk\WyuczD4[Y5w\3KjZoTl[EBifGi7bXnjJI1wfXOnIHH0JFYvOjVibXevb4ctKHCxLDDDcYF5KD1iND61JO69VS5? NXnSfG9nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOlA4OTFpPkG5NlYxPzFzPD;hQi=>
GTL16 NXL4[5dnTnWwY4Tpc44h[XO|YYm= NX\B[HBGPTBibXevb4c> MnXCR41igCCrbjDoeY1idiCJVFyxOkBk\WyuczD4[Y5w\3KjZoTl[EBifGi7bXnjJI1wfXOnIHH0JFUxKG2pL3vnMEBxdyxiQ33hfEA:KDR|Lkeg{txONg>? NGG1ZYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK2NFcyOSd-MUmyOlA4OTF:L3G+
SJ-GBM2 M4nEcJFJXFNiYYPzZZk> NWHQPYNXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> NV7LZ|FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NFXWbFFyUFSVIHHzd4F6 NXTTNYlkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NYTxc41DeUiWUzDhd5NigQ>? M4LISZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz MnzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NVX1PWNQeUiWUzDhd5NigQ>? NFzKS4tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 NHHRVnlyUFSVIHHzd4F6 MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? NVn0TlE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NEPCZnpyUFSVIHHzd4F6 NYrCb3A5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MmLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 M3HUTZFJXFNiYYPzZZk> MnPZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NVT5WZJNeUiWUzDhd5NigQ>? NHi0SW5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| NX3CPIJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 M124fZFJXFNiYYPzZZk> M3m5S5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 MXXxTHRUKGG|c3H5 MmXDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) M{\aUJFJXFNiYYPzZZk> MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MGHU3 NULPZYtlSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MkXCO|IhcHK| MmjBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPR1jVN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeR?= Ml[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|MEm2O|EoRjNyM{C5OlcyRC:jPh?=
RT112 MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVPuOmo2PzJiaILz M2LBN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmSxNVIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYm= NIS1T|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEOwPVY4OSd-M{CzNFk3PzF:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-Met / c-Met / p-FAK / p-c-Src / p-Akt / p-S6K / p-S6; 

PubMed: 22639908     


Effect of BMS-777607 on c-Met signaling in PC-3 cells PC-3 cells were treated with indicated doses of BMS-777607 for 1 h (A) or with BMS-777607 (1 μM) for indicated times (B). Whole cell lysates were harvested and analyzed by Western blot, with actin as a loading control. Data represent 1 of 2 independent experiments.

p53 / p21 / Survivin / p-Rb / Rb ; 

PubMed: 24444656     


BMS-777607 increases p21/WAF1 and survivin expression but down-regulates Rb expression. T-47D and ZR-75-1 cells were treated with 5 μM BMS-777607 for different time intervals. Cellular proteins (50 μg per sample) from cell lysates were subjected to Western blot analysis using individual antibodies specific to p53, p21/WAF1, survivin, regular and phospho-Rb. B-actin was used as the loading control.

22639908 24444656
Immunofluorescence
α-tubulin / survivin; 

PubMed: 24444656     


Abnormal accumulation of survivin and its disassociation with condensed DNA and mitotic spindle. Both T-47D and ZR-75-1 cells were treated with 5 μM BMS-777607 for 72 h followed by immunofluorescent analysis using antibodies specific to survivin and α-tubulin. Cells were also stained with DAPI for nuclear DNA. Images shown here are from one of two experiments with similar results.

24444656
体内研究 BMS 777607按6.25-50 mg/kg剂量口服处理给药携带GTL-16人类移植瘤的无胸腺小鼠,明显降低肿瘤体积,且没有毒性。[1] BMS 777607按25 mg/kg剂量每天处理6-8周大的注射啮齿类纤维肉瘤KHT细胞的雌性C3H/HeJ小鼠,降低 KHT肺肿瘤结节数量,提高形态出血, 且明显修复损害转移表型,与对照组相比,没有明显毒性。BMS 777607按 10 mg/kg 低剂量处理,也适度但不显著抑制肺结节形成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[4]
- 合并

Met Kinase Assay:

The kinase reaction consists of baculovirus expressed GST-Met, 3 μg of poly(Glu/Tyr), 0.12 μCi 33P γ-ATP, 1 μM ATP in 30 μL of kinase buffer (20 mM Tris-Cl, 5 mM MnCl2, 0.1 mg/mL BSA, 0.5 mM DTT). Reactions are incubated for 1 hour at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 8%. TCA precipitates are collected onto GF/C unifilter plates using a Filtermate universal harvester, and the filters are quantitated using a TopCount 96-well liquid scintillation counter. Dose response curves are generated to determine the concentration required to inhibit 50% of substrate phosphorylation (IC50). BMS 777607 is dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at 10 concentrations, in duplicate.
细胞实验:[3]
- 合并
  • Cell lines: 啮齿类纤维肉瘤KHT细胞
  • Concentrations: 溶于DMSO,作为储存液(10 mM), 终浓度为10 μM 左右
  • Incubation Time: 2, 24和96小时
  • Method: 用连续稀释的BMS 777607 处理KHT细胞96小时,然后进行MTT实验和台酚蓝排除,分别测定细胞增殖和细胞死亡。KHT细胞集落和BMS 777607温育24小时,然后用结晶紫(0.1%)染色,然后显影,测定细胞分散情况。使用无菌的1 ml吸管端在融合的KHT单层细胞上划2 mm 痕,随后用BMS-777607处理24小时,在4块随机区域中计数迁移到剥蚀地细胞数,用于测定细胞迁移情况。为了测定细胞入侵,用Matrigel预包被的转移嵌入板(8 μm 孔膜),和无血清培养基在有或无BMS 777607存在时,在37oC下温育2小时,使Matrigel再水化。悬浮在无血清培养基上的细胞装到小室顶端,悬浮在含10% FBS的完全培养基上的细胞装到小室底端,作为化学引诱物。温育24小时,移除 Matrigel,用结晶紫染色。显影并计数在滤液下面的入侵细胞。
    (Only for Reference)
动物实验:[3]
- 合并
  • Animal Models: 携带啮齿类纤维肉瘤KHT细胞的雌性C3H/HeJ小鼠
  • Dosages: 10-25 mg/kg
  • Administration: 饲喂处理,每天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 47 mg/mL (91.63 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+45% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 512.89
化学式

C25H19ClF2N4O4

CAS号 1025720-94-8
储存条件 粉状
溶于溶剂
别名 BMS 817378

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01721148 Completed Drug: ASLAN002( BMS 777607) Malignant Solid Tumour Aslan Pharmaceuticals October 2012 Phase 1
NCT00605618 Completed Drug: BMS-777607 Advanced Solid Tumors Bristol-Myers Squibb March 2008 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What formulation can we use to dissolve S1561 for mice in vivo study?

  • 回答:

    S1561 BMS-777607 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30 mg/ml is a suspension. It is fine for oral gavage. If you are going to use it for injection, please try the following vehicle: 4% DMSO+30% PEG 300+ddH2O. BMS-777607 can be dissolved in it at 5 mg/ml as a clear solution.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买BMS-777607 | BMS-777607供应商 | 采购BMS-777607 | BMS-777607价格 | BMS-777607生产 | 订购BMS-777607 | BMS-777607代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID